drugset / Trial / NCT05065892
Evaluation of Immunogenicity and Safety of COVID-19 Vaccine (Produced in Wuhan) in Patients With Hypertension and/or Diabetes
Phase 4
Unknown
1440 enrolled
China National Biotec Group Company Limited
Center for Disease Control and Prevention, Fujian · collabGuizhou Center for Disease Control and Prevention · collabHunan Provincial Center for Disease Control and Prevention · collabWuhan Institute of Biological Products Co., Ltd · collab
Non-randomizedParallel-groupSingle-blindPrevention
Summary
To evaluate the post-marketing immunogenicity and safety of the inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine (Vero cells) in patients aged 60 years or older with hypertension and/or diabetes, thus to further collect the immunogenicity and safety data of this product in special populations.
Timeline
- Start
- 2021-10
- Primary completion
- 2022-01
- Completion
- 2022-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | COVAX | Vaccine | — | — |